• About Us • Mission & Values • Management Team • Board of Directors • Board Committees • Commercial Capabilities • Corporate Responsibility • Ethical Sales & Marketing • Drug Safety & Medical Info • Physician Data Restriction Program • California Compliance Declaration • Stories • What’s in a Name? • Business Development • Locations ABOUT US Jazz Pharmaceuticals plc is an international specialty biopharmaceutical company dedicated to helping patients with unmet medical needs. We identify, develop and commercialize innovative products in focused therapeutic areas, with a strong commercial focus and expertise in narcolepsy, oncology, pain and psychiatry. Our marketed product portfolio includes: XYREM® (sodium oxybate), ERWINAZETM (asparaginase Erwinia chrysanthemi), PRIALT® (ziconotide) solution, intrathecal infusion, FAZACLO® (clozapine, USP) LD and HD , and LUVOX CR® (fluvoxamine maleate). The product information on XYREM, ERWINAZE, PRIALT, FAZACLO LD, FAZACLO HD and LUVOX CR is intended only for residents of the United States. For more information, including complete prescribing information and boxed warnings, click on the product names above. Please visit www.EUSAPharma.com for more information about our international division, EUSA Pharma, and our products marketed outside the U.S. We plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our unique commercial expertise. As we evaluate additional acquisition and in-licensing opportunities, we work closely with healthcare professionals and patient advocates to identify significant treatment gaps where Jazz Pharmaceuticals’ unique approach to patient care and patient-focused products may be able to bring a new therapeutic option to the market where none existed previously.

Ipsen SA manufactures pharmaceutical products for oncology, neuroscience and rare diseases. It operates through following segments: Specialty Care and Consumer Healthcare. The Specialty Care segment focuses on Oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and Rare Diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin. The Consumer Healthcare segment include brands such as Smecta, a naturally extracted purified clay for the symptomatic treatment of acute diarrhea; Tanakan, a standardized extract from the leaves of Ginkgo biloba for the treatment of various neurological and neuro-sens or ial disorders; Forlax, an osmotic laxative indicated for the symptomatic treatment of constipation in adults and children; and Fortrans, a colon cleansing solution indicated for patients in preparation for endoscopic, radiological examinations or colonic surgery. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France.

FirstGroup Plc engages in the provision of passenger transport services. It operates through the following segments: First Student, First Transit, Greyhound, First Bus, and First Rail. The First Student segment provides transportation among students in North America. The First Transit segment offers public transit management and contracting services in North America. The Greyhound segment refers to operation of schedules intercity couch transportation services in the United States and Canada. The First Bus segment is the operation of bus in United Kingdom and outside London. The First Rail segment is the operation and management of rail transportation with open access system. The company was founded on March 31, 1995 and is headquartered in Aberdeen, the United Kingdom.